Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orthocell Ltd ( (AU:OCC) ) just unveiled an announcement.
Orthocell Limited has issued 1,563,271 fully paid ordinary shares following the cashless exercise of unlisted options, allowing immediate trading under section 708A(5) of the Corporations Act. This move reflects Orthocell’s ongoing compliance with regulatory requirements and could enhance its market liquidity, potentially benefiting stakeholders by improving the company’s financial flexibility.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company that focuses on developing products to repair bone and soft tissue injuries, enhancing patient mobility. Its product portfolio includes collagen medical devices for tissue reconstruction, with Striate+™ approved for dental applications globally and Remplir™ for nerve reconstruction cleared in the US and other regions. The company is also advancing tendon cell therapy in the US.
Average Trading Volume: 544,192
Technical Sentiment Signal: Buy
Current Market Cap: A$306.6M
See more insights into OCC stock on TipRanks’ Stock Analysis page.